Drug intelligence / Profile preview

SKA-19

Development stage: Unknown
Lead developer: SATO Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

SKA-19 is an investigational drug candidate being developed by Sato Pharmaceutical for the treatment of inflammatory skin disorders. It is a licensed-in compound from an undisclosed overseas partner. As of early 2024, the drug is in the preparatory stages for Phase 3 clinical development in Japan. While the specific molecular target and mechanism of action have not been publicly disclosed by Sato, the company's research and development strategy focuses heavily on low-molecular-weight (small molecule) drug discovery for dermatological and other specialized therapeutic areas.

Beyond the preview

Go deeper on SKA-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKA-19.

Explore the full profile